Sotorasib的加速批准

IF 22.5 1区医学 Q1 ONCOLOGY

JAMA Oncology Pub Date : 2025-03-13 DOI:10.1001/jamaoncol.2025.0039

Mark J. Ratain, Aaron S. Kesselheim

引用次数: 0

摘要

本观点回顾了加速审批过程和缺乏批准后研究来验证其用于治疗KRASg12c突变的非小细胞肺癌药物sotorasib的益处，并建议采取措施确保验证性后续研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sotorasib’s Accelerated Approval

This Viewpoint reviews the accelerated approval process and lack of postapproval studies to verify its benefit as it applied to sotorasib, a treatment for non–small cell lung cancer with the KRASg12c mutation, and recommends measures to ensure confirmatory follow-up studies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.